ACADIA Pharmaceuticals マネジメント
マネジメント 基準チェック /24
現在、CEO に関する十分な情報がありません。
主要情報
Catherine Owen Adams
最高経営責任者
n/a
報酬総額
| CEO給与比率 | n/a |
| CEO在任期間 | less than a year |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 2yrs |
| 取締役会の平均在任期間 | 9yrs |
経営陣の近況
Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18CEO（最高経営責任者
Catherine Owen Adams (54 yo)
less than a year
在職期間
Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. Ms. Owen Adams served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She se...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive VP & CFO | 3.2yrs | US$2.59m | 0.032% $ 881.5k | |
| Executive VP | 3yrs | US$2.62m | 0.037% $ 1.0m | |
| Consultant | less than a year | US$7.59m | 0.11% $ 3.1m | |
| CEO & Director | less than a year | データなし | データなし | |
| VP, Chief Accounting Officer & Corporate Controller | 4.3yrs | データなし | 0.012% $ 328.6k | |
| Executive VP and Head of Research & Development | less than a year | データなし | データなし | |
| Senior Vice President of Technical Development | 2yrs | データなし | データなし | |
| Senior Vice President of Investor Relations & Corporate Communications | 1.2yrs | データなし | データなし | |
| Executive VP | less than a year | データなし | データなし | |
| Senior VP & Head of Sales | 2.8yrs | データなし | データなし | |
| Senior VP & Chief People Officer | 2.8yrs | データなし | データなし | |
| Senior Vice President of New Product Planning & Strategy | no data | データなし | データなし |
2.0yrs
平均在職期間
54yo
平均年齢
経験豊富な経営陣: ACADの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | less than a year | データなし | データなし | |
| Independent Director | 16.5yrs | US$392.75k | 0.012% $ 333.3k | |
| Independent Director | 8.9yrs | US$377.75k | 0.062% $ 1.7m | |
| Member of the Scientific and Clinical Advisory Board | no data | データなし | データなし | |
| Independent Director | 9yrs | US$387.75k | 0.015% $ 424.4k | |
| Independent Director | 9.7yrs | US$387.75k | 0.021% $ 573.3k | |
| Member of the Scientific and Clinical Advisory Board | no data | データなし | データなし | |
| Member of the Scientific and Clinical Advisory Board | no data | データなし | データなし | |
| Member of the Scientific and Clinical Advisory Board | no data | データなし | データなし | |
| Independent Director | 8.8yrs | US$387.75k | 0.015% $ 407.9k | |
| Independent Chairman of the Board | 11.8yrs | US$432.75k | 0.062% $ 1.7m | |
| Independent Director | 4.2yrs | US$377.75k | 0.014% $ 372.4k |
9.0yrs
平均在職期間
66yo
平均年齢
経験豊富なボード: ACADの 取締役会 は 経験豊富 であると考えられます ( 9年の平均在任期間)。